Acne, Mental Health, and Isotretinoin: Disentangling Disease Burden, Treatment Effects, and Psychiatric Risk

Clicks: 3
ID: 315383
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #106 of 176 articles by views in clinical and experimental dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 176 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Acne vulgaris is among the commonest chronic inflammatory skin conditions worldwide and is consistently associated with depression, anxiety, shame, social withdrawal, and impaired quality of life—burdens that are frequently underestimated in routine clinical practice. Simultaneously, isotretinoin, the most effective systemic treatment for severe or scarring acne, remains at the centre of a longstanding debate about psychiatric safety. This narrative review examines evidence on acne-related psychological burden, the bidirectional interaction between acne and mental health, and contemporary data on psychiatric outcomes during isotretinoin therapy. Pooled analyses confirm that patients with acne have substantially elevated rates of depressive symptoms (approximately 22%), anxiety (approximately 29%), and suicidal ideation (approximately 12%), often disproportionate to physician-rated lesion counts. In contrast, the best available population-level evidence does not support a generalised increase in suicide risk or psychiatric disorders among isotretinoin users; some data suggest a reduction in suicide attempt rates in the years following treatment. Pharmacovigilance signals persist but are hypothesis-generating rather than causal, and principally support structured monitoring in vulnerable subgroups. The core clinical task is not to determine whether isotretinoin is universally safe or dangerous, but to distinguish three concurrent forces: psychosocial burden attributable to acne itself, pre-existing psychiatric vulnerability, and rare treatment-emergent events. A pragmatic monitoring model that integrates baseline psychiatric screening, longitudinal follow-up, and shared decision-making is more useful than binary risk labelling. Addressing visible inflammation and invisible suffering together represents the standard to which acne care should aspire.
Reference Key
openalex_W7162865549 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Rafael Tonella Vezzoli
Journal clinical and experimental dermatology
Year 2026
DOI
10.1093/ced/llag231
URL
https://doi.org/10.1093/ced/llag231
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.